Pivotal Phase 3 BOND-003 Study Results Published in The Lancet Oncology Show Durable Responses in Bladder Cancer

CG Oncology announced the publication of results from the pivotal Phase 3 BOND-003 Cohort C trial in The Lancet Oncology. The study demonstrated high complete response rates and durable bladder preservation with cretostimogene grenadenorepvec monotherapy in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer.